Initiatives to support antibiotic research — of which TB drug and diagnostic R&D are crucial parts — must be backed by funding commensurate to the growing size of the epidemic.

In the second of two linked posts (you can read the first one here), Lindsay McKenna and Colleen Daniels of Treatment Action Group (TAG) describe the importance of access to timely diagnosis and appropriate treatment for patients with drug-resistant tuberculosis and demand that urgency be returned to the global DR-TB response.